Study #2023-0004
ONC201 for the treatment of newly diagnosed H3 K27M-mutant diffuse glioma following completion of radiotherapy: A randomized, double-blind, placebo-controlled, multicenter study
MD Anderson Study Status
Enrolling
Treatment Agent
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo
Description
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
H3 K27M, Glioma
Study phase:
Phase III
Physician name:
Nazanin Majd
Department:
Neuro-Oncology
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.